Resilience Demonstrates Lower Cost of Perfusion Bioreactor Process Using 908 Devices’ REBEL At-line Analyzer

908 Devices Inc., (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announced that National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, has adopted REBEL at-line media analyzers in their process development to inform and optimize cell culture feed strategies and media design. REBEL provides insights into cell metabolism to enable Resilience process engineers to measure spent media samples to monitor amino acid depletion during a monoclonal antibody perfusion process. Resilience demonstrated, using REBEL, a 50% increase in titer while reducing cost of goods by adding back only the nutrients the cells have depleted.

“Data from the REBEL enables our teams to improve the speed of development, allowing for rapid optimization of our media feeds,” said Andy Grube, Director of Upstream Process Development, Biologics Franchise at Resilience. “Cell culture media and feed costs are significant in a perfusion process. With at-line media analysis, we can optimize and accelerate biotherapeutic development, with the ultimate goal of reducing cost of goods and time to submission.”

Resilience engineers are researching various techniques to lower the cost of media used in a perfusion process. At-line media analysis enables process development engineers to make decisions throughout the bioreactor run and inform feeding models, thereby improving cell culture outcomes and maximizing bioreactor utilization. At-line media analysis may further enable biopharma to characterize process consistency via media “finger printing” and process monitoring.

About the REBEL analyzer

REBEL is a first-of-its-kind fresh and spent media analyzer that enables biopharma researchers to accelerate process development cycles and maximize bioreactor utilization by running media analysis at-line. Key benefits include:

• Efficiency – minimal sample preparation and tiny volume requirements
• Real-time data tracking – quantitate over 30 key media nutrients in <10 minutes
• Small and simple – versatile design valued by users across many applications

For more information, visit www.908devices.com.

About Resilience

Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit https://resilience.com.

About 908 Devices

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005242/en/

Data from the REBEL at-line media analyzer enables our teams to optimize and accelerate biotherapeutic development, with the ultimate goal of reducing cost of goods and time to submission.